SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:daa49fd6-b2c7-4a45-af27-870ce7227d84"
 

Search: id:"swepub:oai:lup.lub.lu.se:daa49fd6-b2c7-4a45-af27-870ce7227d84" > The Hidden Side of ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Serrano, InmaculadaBellvitge University Hospital-IDIBELL (author)

The Hidden Side of Complement Regulator C4BP : Dissection and Evaluation of Its Immunomodulatory Activity

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-04-25
  • Frontiers Media SA,2022

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:daa49fd6-b2c7-4a45-af27-870ce7227d84
  • https://lup.lub.lu.se/record/daa49fd6-b2c7-4a45-af27-870ce7227d84URI
  • https://doi.org/10.3389/fimmu.2022.883743DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(β-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the β-chain to the C4BP α-chain oligomer interferes with this immunomodulatory activity of C4BP. Moreover, an oligomeric form including only the complement control protein 6 (CCP6) domain of the C4BP α-chain (PRP6-HO7) is sufficient to “reprogram” monocyte-derived DCs (Mo-DCs) from a pro-inflammatory and immunogenic phenotype to an anti-inflammatory and tolerogenic state. PRP6-HO7 lacks complement regulatory activity but retains full immunomodulatory activity over inflammatory Mo-DCs induced by TLRs, characterized by downregulation of relevant surface markers such as CD83, HLA-DR, co-stimulatory molecules such as CD86, CD80 and CD40, and pro-inflammatory cytokines such as IL-12 and TNF-α. Furthermore, PRP6-HO7-treated Mo-DCs shows increased endocytosis, significantly reduced CCR7 expression and CCL21-mediated chemotaxis, and prevents T cell alloproliferation. Finally, PRP6-HO7 shows also full immunomodulatory activity over Mo-DCs isolated from lupus nephritis patients with active disease, even without further pro-inflammatory stimulation. Therefore PRP6-HO7, retaining the immunomodulatory activity of C4BP(β-) and lacking its complement regulatory activity, might represent a promising and novel alternative to treat autoimmune diseases.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Luque, AnaBellvitge University Hospital-IDIBELL (author)
  • Mitjavila, FrancescaBellvitge University Hospital-IDIBELL (author)
  • Blom, Anna M.Lund University,Lunds universitet,Institutionen för translationell medicin,Medicinska fakulteten,Proteinkemi, Malmö,Forskargrupper vid Lunds universitet,Department of Translational Medicine,Faculty of Medicine,Protein Chemistry, Malmö,Lund University Research Groups(Swepub:lu)klke-abl (author)
  • Rodríguez de Córdoba, SantiagoCSIC Spanish National Research Council (author)
  • Vega, M. CristinaCSIC Spanish National Research Council (author)
  • Torras, JoanBellvitge University Hospital-IDIBELL (author)
  • Aran, Josep M.Bellvitge University Hospital-IDIBELL (author)
  • Bellvitge University Hospital-IDIBELLInstitutionen för translationell medicin (creator_code:org_t)

Related titles

  • In:Frontiers in Immunology: Frontiers Media SA131664-3224

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view